Cargando…

MONOCLONAL GAMMOPATHY OF CLINICAL SIGNIFICANCE

Detalles Bibliográficos
Autor principal:	Bladé, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Main Program
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171576/ http://dx.doi.org/10.1097/01.HS9.0000936060.22155.90

Ejemplares similares

HOW TO INCORPORATE MRD IN CLINICAL TRIALS
por: San-Miguel, Jesus
Publicado: (2022)

MASS SPECTROMETRY AS A TOOL FOR MINIMAL RESIDUAL DISEASE DETECTION IN THE BLOOD OF MYELOMA PATIENTS
por: Jacobs, J.F.M.
Publicado: (2023)

AL AMYLOIDOSIS UPFRONT TREATMENT AND CURRENT AND FUTURE STUDIES
por: Kastritis, E.
Publicado: (2023)

EARLY DETECTION AND SCREENING FOR MULTIPLE MYELOMA PRECURSORS
por: Thorsteinsdottir, S.
Publicado: (2023)

BONE DISEASE
por: Terpos, E.
Publicado: (2023)

MGRS: DIAGNOSIS AND TREATMENT
por: Bridoux, F.
Publicado: (2023)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

HOW TO HARNESS NEW IMMUNOTHERAPIES WITH COMBINATION STRATEGIES?
por: Einsele, H.
Publicado: (2023)

TREATMENT OF TRIPLE-CLASS REFRACTORY DISEASE: BEYOND IMMUNOTHERAPY
por: Gavriatopoulou, M.
Publicado: (2023)

DEBATE UPFRONT vs DELAYED TRANSPLANT
por: Gay, F.
Publicado: (2023)

FROM BENIGN TO MALIGNANT DISEASE
por: Bolli, Niccolò
Publicado: (2022)

THE ATLAS INITIATIVE AND HOW TO IMPROVE ACCESS FOR PATIENTS
por: Morgan, Kate
Publicado: (2022)

MINIMAL RESIDUAL DISEASE IN PERIPHERAL BLOOD ASSESSED BY MASS SPECTROMETRY
por: Puig, Noemi
Publicado: (2022)

HOW TO TREAT UNFIT AND FRAIL PATIENTS
por: Cook, Gordon
Publicado: (2022)

DRUGGABLE MM THERAPEUTICS: PATHOGENETIC PATHWAYS
por: Ocio, Enrique M
Publicado: (2022)

LIGHT CHAIN DEPOSITION DISEASE
por: Vos, Josephine M.I.
Publicado: (2022)

BONE DISEASE
por: Terpos, Evangelos
Publicado: (2022)

EXTRAMEDULLARY DISEASE
por: Beksac, Meral
Publicado: (2022)

AL AMYLOIDOSIS: MECHANISMS OF DISEASE AND BIOMARKERS
por: Palladini, Giovanni, et al.
Publicado: (2022)

COVID-19 AND MYELOMA
por: Ludwig, H, et al.
Publicado: (2022)

IMMUNOTHERAPY
por: Einsele, Hermann
Publicado: (2022)

HOW TO TREAT HIGH RISK PATIENTS
por: Kaiser, Martin
Publicado: (2022)

CIRCULATING TUMOR CELLS
por: Paiva, Bruno
Publicado: (2022)

TREATMENT AT RELAPSE: WHAT TO DO FIRST?
por: Mateos, Maria-Victoria
Publicado: (2022)

Treatment of Patients with Monoclonal Gammopathy of Clinical Significance
por: Moreno, David F., et al.
Publicado: (2021)

The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance
por: Castillo, Jorge J., et al.
Publicado: (2021)

Monoclonal gammopathy of undetermined significance: a contraindication for living kidney donation?
por: Serra, Nuria, et al.
Publicado: (2011)

Monoclonal Gammopathy of Thrombotic Significance
por: Gkalea, Vasiliki, et al.
Publicado: (2023)

Monoclonal gammopathy of “ocular” significance
por: Karakus, Sezen, et al.
Publicado: (2019)

Diagnosis and management of monoclonal gammopathy of clinical significance
por: Cho, Hyungwoo
Publicado: (2022)

Immunoglobulin M Monoclonal Gammopathies of Clinical Significance
por: Girard, Louis-Pierre, et al.
Publicado: (2022)

Monoclonal Gammopathies of Clinical Significance: A Critical Appraisal
por: Ríos-Tamayo, Rafael, et al.
Publicado: (2022)

Editorial: Monoclonal gammopathies of clinical significance: Clinical and therapeutic implications
por: Wang, Chen, et al.
Publicado: (2023)

Immunophenotypic studies of monoclonal gammopathy of undetermined significance
por: Olteanu, Horatiu, et al.
Publicado: (2008)

Monoclonal gammopathy of renal significance: case report
por: Fonseca, Gabriela Spacek da, et al.
Publicado: (2018)

Monoclonal Gammopathy of Undetermined Significance-associated Scleromyxoedema
por: Baxi, Kalgi D., et al.
Publicado: (2019)

Monoclonal gammopathy of renal significance: Diagnostic workup
por: Correia, Sofia O, et al.
Publicado: (2017)

Kidney Transplantation and Monoclonal Gammopathy of Undetermined Significance
por: Aslam, Nabeel, et al.
Publicado: (2021)

Monoclonal gammopathy of increasing significance: time to screen?
por: Chen, Lucia Y., et al.
Publicado: (2022)

IgM monoclonal gammopathies of clinical significance: diagnosis and management
por: Khwaja, Jahanzaib, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_33ic9k9ab98522eedj5d8ktseu